Abstract
Background Urinary tract infection (UTI) is a recognized complication of shock wave lithotripsy (SWL) for urolithiasis. Evidence guiding antibiotic prophylaxis remains of low certainty, contributing to substantial practice variation and conflicting guidelines. A well-powered, blinded randomized trial is essential to provide trustworthy evidence for clinical practice. Study Design An international, multicentre, randomized controlled trial (the APPEAL trial) assessing the benefits and harms of a single dose of ciprofloxacin versus placebo before SWL in reducing post-procedure UTI. Patients, healthcare providers, data collectors, outcome adjudicators and statisticians blinded to treatment assignment. Endpoints Appeal's primary outcome is bacteriuria or symptomatic UTI (symptomatic UTI defined as symptomatic cystitis, pyelonephritis, or urosepsis) within approximately 7-14 days post-SWL. Other outcomes include pyelonephritis or urosepsis, and serious adverse events. Patients and Methods Over 1,500 patients from high- and middle-income countries undergoing SWL for nephrolithiasis or ureterolithiasis. Exclusion criteria include a positive pre-SWL urine analysis for nitrites or urine culture, ongoing or planned antibiotic use, suspected struvite stones, urinary catheters or diversion, or a history of urosepsis. Imminent report of APPEAL will provide high-quality evidence on the role of antibiotic prophylaxis in SWL and identify subgroups that may benefit most. Trial Registration ClinicalTrial.gov identifier (ID): NCT03692715. Keywords antibiotic prophylaxis; clinical trials; lithotripsy; randomized controlled trial; statistical analysis; urinary tract infections; urolithiasis
Competing Interest Statement
Le Mai Tu has received speaker honoraria from Abbvie, Astellas and Fotona. Thomas Tailly is company consultant for Ambu GmbH, Cook Medical, Storz Medical AG, Photocure, Dornier Med Tech GmbH, BD; received speaker honoraria from Boston Scientific; and is panel member of the EAU Guidelines on Urolithiasis. Patrick O Richard is company consultant for Novartis and has received speaker honoraria from Astellas, Abbvie, Bayer, Knight, Novartis and Tolmar. Murilo de Almeida Luz is company consultant for Astellas, Janssen and ProScan; received speaker honoraria from Astellas, Bayer, Ipsen, Janssen and Sanofi; has received research grants from Amgen, Astra-Zeneca, Ferring and ProScan; participates in trials for Active Biotech, Bayer, Ferring, GSK and Janssen; and has received travel grants from Astra-Zeneca, Bayer, Janssen and Pfizer. Samuel Lagabrielle is company consultant for Alnylam and Boston Scientific; and has received speaker honoraria from Alnylam and Boston Scientific. John Denstedt has received royalties from Cook Medical, speaker honoraria from Becton Dickenson and Boston Scientific; and research grants from Vathin Medical. Other authors declare no conflicts of interest.
Clinical Protocols
https://clinicaltrials.gov/study/NCT03692715
Funding Statement
Funded by the Competitive Research Fund of the Helsinki and Uusimaa Hospital District (TYH2017114, TYH2018120; TYH2019321, TYH2020248, TYH2022330, TYH2023236), Sigrid Juselius Foundation, Research Council of Finland (309387), Vyborg Tuberculosis Foundation, Physicians' Services Incorporated Foundation, Lawson Health Research Institute, Quebec Urological Association Scholarship Fund and Dr H. Olding and Mrs J. Hildigar Foucar Memorial Fund. The sponsors had no role in the study design or in manuscript preparation, review or approval.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
